Literature DB >> 25728472

GABA Deficits Enhance the Psychotomimetic Effects of Δ9-THC.

Rajiv Radhakrishnan1, Patrick D Skosnik2, Jose Cortes-Briones1, R Andrew Sewell1, Michelle Carbuto1, Ashley Schnakenberg1, John Cahill2, Fred Bois2, Handan Gunduz-Bruce2, Brian Pittman3, Mohini Ranganathan1, Deepak Cyril D'Souza1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25728472      PMCID： PMC4839528          DOI： 10.1038/npp.2015.58

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  50 in total

1.  Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of δ-9-tetrahydrocannabinol on midbrain and striatal function.

Authors:  S Bhattacharyya; Z Atakan; R Martin-Santos; J A Crippa; J Kambeitz; D Prata; S Williams; M Brammer; D A Collier; P K McGuire
Journal:  Mol Psychiatry       Date:  2012-01-31       Impact factor: 15.992

2.  Ultrasensitive measurement of delta-9-tetrahydrocannabinol with a high energy dynode detector and electron-capture negative chemical-ionization mass spectrometry.

Authors:  L M Shaw; J Edling-Owens; R Mattes
Journal:  Clin Chem       Date:  1991-12       Impact factor: 8.327

3.  The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation.

Authors:  S R Kay; L A Opler; J P Lindenmayer
Journal:  Br J Psychiatry Suppl       Date:  1989-11

Review 4.  The GABA-ergic system: a locus of benzodiazepine action.

Authors:  J F Tallman; D W Gallager
Journal:  Annu Rev Neurosci       Date:  1985       Impact factor: 12.449

5.  Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex.

Authors:  S M Eggan; D S Melchitzky; S R Sesack; K N Fish; D A Lewis
Journal:  Neuroscience       Date:  2010-06-11       Impact factor: 3.590

Review 6.  A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research.

Authors:  Steven J Luck; Daniel H Mathalon; Brian F O'Donnell; Matti S Hämäläinen; Kevin M Spencer; Daniel C Javitt; Peter J Uhlhaas
Journal:  Biol Psychiatry       Date:  2010-12-15       Impact factor: 13.382

7.  Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

Authors:  Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

8.  GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression.

Authors:  Jong H Yoon; Richard J Maddock; Ariel Rokem; Michael A Silver; Michael J Minzenberg; J Daniel Ragland; Cameron S Carter
Journal:  J Neurosci       Date:  2010-03-10       Impact factor: 6.167

Review 9.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Authors:  Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis
Journal:  Lancet       Date:  2007-07-28       Impact factor: 79.321

10.  Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.

Authors:  Patrik Roser; Georg Juckel; Johannes Rentzsch; Thomas Nadulski; Jürgen Gallinat; Andreas M Stadelmann
Journal:  Eur Neuropsychopharmacol       Date:  2008-06-10       Impact factor: 4.600
View more
  14 in total

1.  Adolescent Δ9-Tetrahydrocannabinol Exposure and Astrocyte-Specific Genetic Vulnerability Converge on Nuclear Factor-κB-Cyclooxygenase-2 Signaling to Impair Memory in Adulthood.

Authors:  Yan Jouroukhin; Xiaolei Zhu; Alexey V Shevelkin; Yuto Hasegawa; Bagrat Abazyan; Atsushi Saito; Jonathan Pevsner; Atsushi Kamiya; Mikhail V Pletnikov
Journal:  Biol Psychiatry       Date:  2018-08-16       Impact factor: 13.382

Review 2.  The why behind the high: determinants of neurocognition during acute cannabis exposure.

Authors:  Johannes G Ramaekers; Natasha L Mason; Lilian Kloft; Eef L Theunissen
Journal:  Nat Rev Neurosci       Date:  2021-05-27       Impact factor: 34.870

3.  Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies.

Authors:  Suhas Ganesh; Jose Cortes-Briones; Mohini Ranganathan; Rajiv Radhakrishnan; Patrick D Skosnik; Deepak Cyril D'Souza
Journal:  Int J Neuropsychopharmacol       Date:  2020-12-03       Impact factor: 5.176

Review 4.  New vistas on cannabis use disorder.

Authors:  Miriam Melis; Roberto Frau; Peter W Kalivas; Sade Spencer; Vivian Chioma; Erica Zamberletti; Tiziana Rubino; Daniela Parolaro
Journal:  Neuropharmacology       Date:  2017-03-31       Impact factor: 5.250

5.  Δ9-THC reduces reward-related brain activity in healthy adults.

Authors:  Conor H Murray; James E Glazer; Royce Lee; Robin Nusslock; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2022-05-25       Impact factor: 4.415

6.  Involvement of the orexin/hypocretin system in the pharmacological effects induced by Δ(9) -tetrahydrocannabinol.

Authors:  África Flores; Marina Julià-Hernández; Rafael Maldonado; Fernando Berrendero
Journal:  Br J Pharmacol       Date:  2016-03-03       Impact factor: 8.739

7.  Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: A translational study in rats and humans.

Authors:  Patrick D Skosnik; Mihály Hajós; Jose A Cortes-Briones; Chad R Edwards; Brian P Pittman; William E Hoffmann; Andrew R Sewell; Deepak C D'Souza; Mohini Ranganathan
Journal:  Neuropharmacology       Date:  2018-03-28       Impact factor: 5.250

8.  Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans.

Authors:  Mohini Ranganathan; Joao P De Aquino; Jose A Cortes-Briones; Rajiv Radhakrishnan; Brian Pittman; Savita Bhakta; Deepak C D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2019-06-11       Impact factor: 4.530

9.  Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders.

Authors:  Musa Basseer Sami; Sagnik Bhattacharyya
Journal:  J Psychopharmacol       Date:  2018-03-29       Impact factor: 4.153

Review 10.  The neuropsychopharmacology of cannabis: A review of human imaging studies.

Authors:  Michael A P Bloomfield; Chandni Hindocha; Sebastian F Green; Matthew B Wall; Rachel Lees; Katherine Petrilli; Harry Costello; M Olabisi Ogunbiyi; Matthijs G Bossong; Tom P Freeman
Journal:  Pharmacol Ther       Date:  2018-10-19       Impact factor: 12.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.